Perspective and priorities for improvement of parathyroid hormone (PTH) measurement – A view from the IFCC Working Group for PTH by Sturgeon, Catharine M et al.
1 
 
Perspective and priorities for improvement of parathyroid hormone (PTH) 
measurement – A view from the IFCC Working Group for PTH 
Catharine M Sturgeon*, Stuart Sprague, Alison Almond, Etienne Cavalier, William D 
Fraser, Alicia Schimnich-Algeciras, Ravinder Singh, Jean-Claude Souberbielle & 
Hubert W. Vesper. 
On behalf of the IFCC Working Group for PTH 
C/o Department of Laboratory Medicine, Royal Infirmary of Edinburgh, Edinburgh 
EH16 4SA, UK. 
 
* Corresponding author: 
Catharine Sturgeon, Department of Clinical Biochemistry, Royal Infirmary of 
Edinburgh, Edinburgh EH16 4SA 
Tel: +44 131 242 6885 
Fax: +44 131 242 6882 
E-mail: C.Sturgeon@ed.ac.uk 
 
*Manuscript
2 
 
ABSTRACT 
Parathyroid hormone (PTH) measurement in serum or plasma is a necessary tool for 
the exploration of calcium/phosphorus disorders, and is widely used as a surrogate 
marker to assess skeletal and mineral disorders associated with chronic kidney disease 
(CKD), referred to as CKD-bone mineral disorders (CKD-BMD). CKD currently 
affects more than 10% of the adult population in the United States and represents a 
major health issue worldwide. Disturbances in mineral metabolism and fractures in 
CKD patients are associated with increased morbidity and mortality. Appropriate 
identification and management of CKD-BMD is therefore critical to improving 
clinical outcome. 
Recent increases in understanding of the complex pathophysiology of CKD, which 
involves calcium, phosphorus and magnesium balance, and is also influenced by 
vitamin D status and fibroblast growth factor (FGF) 23 production, should facilitate 
such improvement. Development of evidence-based recommendations about how best 
to use PTH is limited by considerable method-related variation in results, of up to 5-
fold, as well as by lack of clarity about which PTH metabolites these methods 
recognise. This makes it difficult to compare PTH results from different studies and to 
develop common reference intervals and/or decision levels for treatment. The 
implications of these method-related differences for current clinical practice are 
reviewed here. Work being undertaken by the International Federation of Clinical 
Chemistry and Laboratory Medicine (IFCC) to improve the comparability of PTH 
measurements worldwide is also described. 
1. Introduction 
Assessment of parathyroid hormone (PTH) concentration is of paramount importance 
in the exploration of disorders of calcium/phosphorus metabolism and in the 
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monitoring of patients with chronic kidney disease (CKD) in order to ensure that PTH 
concentrations are maintained within guideline limits [1]. With availability of 
convenient and highly precise and reliable automated immunoassay methods for its 
measurement, PTH is now routinely determined in most large clinical laboratories and 
can no longer be considered a specialist test. 
Correct interpretation of a PTH concentration generally requires concomitant serum 
calcium concentration in order to evaluate whether PTH is physiologically appropriate 
(i.e. high calcium with low PTH or low calcium with high PTH) or not (high 
calcium/high PTH or low calcium/low PTH) for the calcium concentration. In clinical 
practice, however, patients may have normal calcium and high PTH or high or low 
calcium and normal PTH [1]. In such patients, measurement of phosphate, urinary 
calcium and 25-hydroxyvitamin D are mandatory.  
PTH measurement is critical to the assessment of patients with primary 
hypoparathyroidism and primary or secondary hyperparathyroidism. However in 
many laboratories the majority of PTH measurements are now performed in patients 
with CKD. In a United Kingdom National External Quality Assessment Service (UK 
NEQAS) Survey of Practice carried out in 2005, 85% of respondents stated that <40% 
of the PTH assays carried out in their laboratories were for patients with primary 
hyperparathyroidism, while 73% reported that >60% of the assays carried out were 
for patients with renal disease [2]. The proportion of the latter is likely to have 
increased in the intervening period, reflecting the continuing worldwide increase in 
the number of patients with CKD. 
A Kidney Disease Improving Global Outcomes (KDIGO) Working Group developed 
the term “CKD-mineral and bone disorders (CKD-MBD)” to encompass the systemic 
changes that occur in CKD patients [3]. These may include (a) metabolic 
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dysregulation of calcium, phosphorus, PTH, fibroblast growth factor (FGF23) and/or 
vitamin D and its metabolites, (b) bone disease or renal osteodystrophy as defined by 
abnormalities in bone turnover, mineralization, linear growth and/or strength, and (c) 
calcification of extra-skeletal tissues include both vascular and other soft tissues  [3].  
It was suggested nearly eighty years ago that development of parathyroid gland 
hyperplasia in patients with CKD-MBD represents a compensatory mechanism for the 
disturbed equilibrium occasioned by phosphate retention due to renal insufficiency. It 
was subsequently recognised that PTH plays a significant role in the aetiology and 
development of CKD-MBD [4] (Figure 1), as increases in PTH occur prior to 
abnormalities in both serum calcium and phosphate concentrations [5, 6]. A reduction 
in intestinal calcium absorption occurs when the glomerular filtration rate decreases. 
This reflects decreased production of 1,25 dihydroxy vitamin D [(1,25(OH)2D] due to 
reduced renal 1–hydroxylase activity which is mediated by increases in FGF23 and 
is associated with phosphate retention. PTH secretion increases in response to the 
changes in 1,25(OH)2D,  calcium and phosphate [5]. However until the development 
of reliable methods for measuring PTH in the 1960s, the diagnosis of 
hyperparathyroidism in patients with CKD-MBD relied on assessment of the effects 
of increased PTH secretion on the skeleton. 
PTH circulates in different molecular forms, including the “intact” (whole) molecule 
(PTH 1-84) and various truncated forms (e.g. PTH 7-84 and smaller fragments). 
These truncated forms may be recognised to different extents in different 
immunoassays (Table 1) as previously reviewed [7, 8]. Early radioimmunoassays 
(RIAs) developed in the 1960s and 1970s frequently detected inactive fragments and 
had relatively poor clinical sensitivity and specificity. Second generation 
immunometric assays (IMAs) developed in the late 1980s were initially thought to be 
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specific for the whole PTH molecule (PTH 1-84) but were subsequently found to 
recognise other circulating fragments as well [9]. Third generation assays which are 
analytically specific for PTH (1-84) are also available. However whether these assays 
are of improved clinical value  as compared to second generation assays has not yet 
been established [10] and they are not yet widely adopted in clinical laboratories.  
Third generation assays provide results in CKD patients that are approximately 50-
60% lower than those obtained with second generation assays and about 15% lower 
than those in subjects without CKD [11], exacerbating the already significant 
between-method differences in results observed for second generation methods [12] 
and (previously) for first generation methods. 
These differences, together with a perceived view that there is inadequate evidence to 
link PTH measurements with adverse skeletal and/or cardiovascular events, have 
recently prompted questioning as to whether PTH measurement in patients with CKD 
is even appropriate or whether it represents a dangerous substitute for identification 
and use of more precise and reliable biomarkers [11]. Additional factors contributing 
to the concerns raised about routine use of PTH measurements in the management of 
CKD patients include issues associated with sample stability, biologic variability and 
sampling site (e.g. central venous catheter sampling vs peripheral blood sampling) 
[11]. 
In a strong rebuttal, it has been pointed out that while PTH assays have shortcomings 
and international standardisation is urgently required, PTH remains the best available 
biomarker with which to guide treatment of CKD-MBD patients, particularly those 
with PTH concentrations toward the extremes of the KDIGO recommendations [13]. 
In such patients, monitoring PTH on a regular basis and instituting treatment to 
decrease elevated PTH concentrations is essential [14], with prospective trials 
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required to determine whether trends in biomarker concentrations could guide 
therapeutic decisions [15]. Bone alkaline phosphatase (bone ALP) measurements have 
not consistently been shown to be superior or additive to PTH and primarily provide 
information  on skeletal function. As PTH is a uraemic toxin, with systemic effects in 
CKD patients reaching far beyond the bone (e.g. proximal myopathy, growth 
retardation in children, anaemia, neurotoxicity, pruritus and cardiomyopathy) due to 
the ubiquitous location of the PTH receptor in multiple tissues, its measurement 
provides additional clinically relevant information [10]. 
While PTH measurement probably remains the best clinically available tool to 
discriminate the extremes of bone turnover [15], it seems likely that both bone ALP 
and PTH can be used to help guide decisions as a “blended approach” [11, 14] when 
the PTH is two to nine times the upper limit of normal, in accord with KDIGO 
recommendations [13]. Serial measurements of PTH are also recommended by 
KDIGO, beginning in CKD Stage 3 since marked changes in PTH even within the 
target PTH range suggest a need for early initiation or change of therapy [16]. 
Most nephrologists consider there is already sufficient evidence linking high or very 
low PTH with adverse outcomes in patients with CKD-MBD. However better 
understanding of the complex disease processes and biological interactions involved 
would be expected to help improve clinical outcome for CKD-MBD patients and 
further research is highly desirable. Whether for research or clinical use, measurement 
of PTH should in future be underpinned by well-standardised and well-characterised 
PTH assays, with evidence-based international guidance outlining pre-analytical and 
other requirements to be followed when designing study protocols. Such rigorous 
attention to detail will be essential to enable reliable comparison of results from 
different studies and centres. It is salutary to note that the poor agreement in PTH 
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results obtained in different methods was a contributory factor when KDIGO 
recommended widening recommended target PTH ranges from three to five times the 
upper limit of normal to two to nine times.  
Here we review how work undertaken by the International Federation of Clinical 
Chemistry and Laboratory Medicine (IFCC)Working Group for PTH will contribute 
to achieving those objectives. With the ultimate aim of facilitating development of a 
complete reference measurement system for PTH determinations, current Working 
Group objectives include  
(1) Achieving standardisation of commercially available PTH measurement methods 
in terms of the same International Standard and implementing this worldwide,  
(2) Defining inclusion and exclusion requirements for an appropriate panel of plasma 
or serum samples with which to establish reference intervals and then to establish 
such a panel, and 
(3) Facilitating development of a candidate reference measurement procedure (RMP) 
for PTH(1-84) to a standard that would enable its adoption by IFCC member national 
societies and its subsequent inclusion of the RMP in the methods supported  the IFCC 
Reference Laboratory Network. 
This standardisation initiative is ambitious but advances in mass spectrometric (MS) 
techniques enable more precise definition of what PTH methods measure, which is an 
essential pre-requisite for development of a reference measurement system [17]. 
Where feasible, standardisation is preferred to harmonization and is likely to be more 
readily sustained in the long-term as harmonization requires maintaining continuity 
and consistency between different reference pools of sera or plasma.  
Measurement of PTH by immunoassay – current state of the art 
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Within-method performance of current automated PTH methods is excellent, with 
within-laboratory within-method coefficients of variation (CVs) <10% demonstrated 
over concentration ranges tested by external quality assessment (proficiency testing) 
schemes [18]. In contrast, between-laboratory between-method CVs are generally 
>20% [19]. 
Between-method variation in results - clinical consequences 
Such method-related differences in PTH results have been convincingly demonstrated 
for some years [7, 18, 20] and have recently been confirmed in a study in which 
variations of up to 4.2-fold in PTH concentrations were observed when PTH was 
measured using five different methods in EDTA plasma from twenty-one 
haemodialysis patients [12]. Figure 2 shows the 3.4-fold difference in results observed 
for one of these patients. Applying Renal Association guidelines current in the UK at 
the time, 7/19 (37%) of the study patients would have been considered to have a 
different category of bone turnover by the highest reading PTH immunoassay than by 
the lowest reading immunoassay. Decisions as to whether medical treatment 
(cinacalcet) or parathyroidectomy should be recommended could also have varied in 
up to 15/19 (79%) of the patients studied [12]. 
Observed variation in PTH results – contributory factors 
In general the major factors that contribute to between-method variation in 
immunoassay results for any analyte include lack of knowledge about what is the 
most clinically relevant PTH analyte to measure, poor calibration or lack of 
calibration against an internationally recognised reference material or reference 
measurement procedure, differences in antibody specificities and/or method design 
such that different isoforms are measured in different assays, and method 
vulnerability to clinically relevant interferences [19]. In order to establish what is 
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most clinically relevant to measure, i.e. the measurand, it is of course first necessary 
to know what PTH isoforms current methods are measuring. However some helpful 
indication of accuracy of calibration, differences in antibody specificities and 
vulnerability to interferences can be acquired from carefully designed external quality 
assessment distributions [21].  
Relative recovery of purified PTH (1-84). Participants in the UK National External 
Quality Assessment Service (UK NEQAS) scheme for PTH receive 24 lyophilised 
PTH specimens annually, at two monthly intervals. While most of these specimens 
contain pooled EDTA plasma from patients with CKD-MBD, some contain known 
amounts of synthetic human PTH(1-84), enabling assessment of relative recoveries, 
i.e. an indication of accuracy. Figure 3 shows the correlation between cumulative bias 
in the UK NEQAS PTH scheme and mean % recovery for three recent recovery 
experiments. Cumulative bias is a statistically valid estimate of deviation from the 
consensus mean target over a period of time, usually 4 to 6 months in the PTH 
scheme.  
The data, which are consistent with those from previous years, suggest that if PTH 
methods were accurately calibrated in terms of the same commutable International 
Standard, between-method agreement would improve.  
Assessment of recognition / cross-reaction of purified PTH (7-84). A similarly 
designed experiment using highly purified PTH(7-84) confirmed significant 
differences in recognition of highly purified PTH(7-84) (Figure 4). As expected the 
3rd Generation DiaSorin method did not recognise this fragment. In patient specimens 
that may contain PTH(7-84), the variable recognition observed is likely to contribute 
to the between-method differences in results observed for the other methods. 
Improving PTH method comparability – IFCC activity 
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Achieving calibration of all PTH assays in terms of a single internationally recognised 
standard such as WHO PTH IS 95/646 [22] is a major goal of the Working Group. At 
least 2-3 years may be required to achieve this as re-standardisation of commercial 
methods is complex and time-consuming. While diagnostic companies supporting the 
IFCC project are in principle supportive of this move, demonstration of the 
commutability of the standard is a pre-requisite [23]. For this it is necessary to show 
experimentally that the standard material and fresh patient specimens exhibit the same 
analytical response (regression line slope about 1.0) when measured by two different 
methods, repeating this activity for all relevant method pairs. The IFCC Scientific 
Division has recently established a Working Group which is developing a protocol for 
formal assessment of commutability that will be used by the PTH Working Group.  
2. Pre-analytical considerations relevant to measurement of PTH 
Defining inclusion and exclusion requirements for a panel of patient specimens 
appropriate for investigating commutability or establishing reference intervals for 
PTH is complex and requires consideration of many potentially confounding factors. 
The most important of these include specimen type and stability, biological variability 
and vitamin D status. As for many analytes, there are few published reports on these 
important issues. Nevertheless, using a rigorous population, intervention, comparator, 
outcome (PICO) approach, a comprehensive electronic search of relevant sources up 
to 6th December 2012 has been undertaken on behalf of the PTH Working Group [24]. 
Only 83 of 5511 papers screened both met the strict criteria defined in the paper for 
inclusion in the systematic review and were relevant to one or more of the three PICO 
questions developed. These all related to specimen type or stability and led to some of 
the recommendations summarised in Table 2. A number of studies described other 
potential pre-analytical influences on PTH concentrations (e.g. potential effects of 
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serum separator tubes [25]) but often reports were few and/or inconsistent. Potential 
influences included food ingestion, vegetarian diet, strenuous exercise, gender, race 
and menopausal status. There were also many limitations to the studies included, most 
of which used as comparator a sample that had been frozen at baseline, a possible 
confounding factor [24]. No direct published comparisons of PTH stability with 
second versus third generation assays were found but such a study would be desirable 
as it is possible that the peptide fragments detected by the second generation assays 
are less stable than the intact molecule detected by third generation assays. In a study 
published after the systematic review, bovine thrombin in rapid serum tubes (RST) 
was found to decrease PTH results relative to results obtained in serum separator 
tubes (SST) by an average of 14.1% after 4h at room temperature [26]. Similar results 
were reported in a second study in which a -15.3% bias was observed for RST tubes 
in one automated method [25]. Authors of the first study suggest that thrombin 
cleavage of PTH may lead to conformational changes that variably affect the 
antigenicity of epitope regions on the molecule and emphasise the importance of 
validating and verifying blood collection tubes[26]. 
Developing specifications for reference panels of plasma for PTH – IFCC activity 
Sourcing appropriate clinical specimens is critically important for commutability and 
other studies to establish or validate metrological traceability, as has been highlighted 
in a recent article which describes difficulties encountered in a similar thyroid 
hormone standardisation project [27]. The IFCC Working Group for PTH is therefore 
carefully considering how best to avoid such pitfalls when developing specifications 
for the planned reference panel, taking heed also of recommendations from the 
systematic review [24]. The same considerations are relevant when acquiring 
specimens for assessment of commutability.  
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Whether and how vitamin D status needs to be taken into account remains 
controversial. As noted above, the definition of vitamin D sufficiency, which may be 
regarded as the 25 hydroxyvitamin D (25OHD) concentration above which PTH 
cannot be suppressed further, varies widely [28] (Table 2). Recently, it has been 
reported that the optimal concentration of 25OHD above which suppression of PTH 
occurs progressively diminishes in CKD patients and is more than twice that currently 
recommended for the general population [29]. It has also been suggested that the 
optimal 25OHD concentration may be higher in CKD patients compared with the 
general population [30]. Two recent guidelines on the diagnosis and management of 
asymptomatic primary hyperparathyroidism strongly recommend that subjects with 
vitamin D insufficiency should be excluded when establishing reference intervals for 
PTH [28, 31]. Reaching consensus about how vitamin D insufficiency should be 
defined is difficult, for reasons that have been recently reviewed [1]. These include 
the between-method variability of current 25OHD assays, which is currently being 
addressed by the Vitamin D Standardization Program [32]. Additional factors 
requiring consideration include diurnal and circadian variation of PTH, renal function, 
and other variables including age, gender, body mass index and race. 
3. Development of a Candidate Reference Measurement Procedure for PTH 
Advances in MS have enabled this technique to be applied to much larger and more 
complex clinically relevant analytes than small molecules such as the steroids for 
which MS reference measurement procedures are now well-established. Rigorous 
physicochemical techniques (e.g. mass spectrometric analysis) are required when 
developing reference measurement procedures, so it is advantageous that there are 
now several published methods for PTH measurement using MS [33-35]. These 
methods can provide accurate and precise PTH results as compared with 
13 
 
immunoassay [34] and can identify and quantify new and previously identified PTH 
fragments [35], which will in the future enable better understanding of the role of the 
PTH isoforms, thereby enabling definition of the clinically relevant compounds to 
measure (i.e. the measurands).  
However further work is required before MS can provide a reference method against 
which other methods should be standardised [33].  
Most problematically, while potentially more analytically specific, the analytical 
sensitivity of currently available MS methods does not match that of more sensitive 
immunoassay methods, although transfer of methods to higher resolution MS may 
overcome this difficulty. Proteolytic digestion of PTH prior to MS analysis is 
required, but it would be desirable to eliminate this step if possible. MS methods can 
also be vulnerable to significant interferences due to the presence of oxidised and 
phosphorylated PTH variants which may accumulate in patient samples [33]. Finally, 
some MS methods rely on a preliminary immunoadsorption step, which means that 
what is ultimately measured is influenced by the particular specificity of the antibody 
or antibodies selected and also (especially for a potential candidate reference method 
procedure) on their long-term stability and availability. 
Developing a candidate reference measurement procedure for PTH – IFCC activity 
In order to assess the feasibility of implementing a MS reference measurement 
procedure for PTH, three sets of 48 freeze-dried specimens that had previously been 
distributed through the UK NEQAS for PTH were analysed by MS at the Mayo Clinic 
[Rochester, Minnesota] using a previously published procedure [34]. Specimens were 
stored at -70C on arrival and each set was reconstituted immediately prior to 
analysis. Results (Figure 5) confirm the feasibility of using the MS method as a 
candidate reference measurement procedure. Results were in excellent agreement with 
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the trimmed all laboratory consensus means used as targets in the UK NEQAS for 
PTH. However until a full reference measurement system is established it is not 
possible to determine whether the UK NEQAS targets for PTH represent “the truth”. 
Also problematically, the MS method used in this study is ten times less sensitive than 
typical immunoassay methods and the between-laboratory reproducibility of the MS 
method has yet to be demonstrated.  
CONCLUSIONS 
Clinical interpretation of currently available PTH assay results is clearly fraught with 
significant governance issues that may adversely affect confidence in the appropriate 
clinical management of CKD-MBD. The activities described above should facilitate 
more meaningful comparison and interpretation of national and international audit 
data and other studies as well as enabling better understanding of how PTH 
measurements should be used in the management of CKD, to benefit patient care 
optimally. Improving the standardisation of PTH methods is clearly feasible although 
ambitious, and the plans presented here will require support from many stakeholders. 
However there is no doubt that with sufficient participation and co-operation from the 
clinical and scientific communities, they are achievable. 
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Table 1. Classification and characteristics of PTH assays 
PTH method classification Usage in clinical 
laboratories 
Method type Antibody characteristics Molecular forms recognised 
1st generation  
 
1960s and 1970s Radioimmunoassay Polyclonal Broad specificity – PTH and 
related fragments 
2nd generation From 1980s onwards Immunometric assay 
(frequently referred 
to as “intact” PTH 
assays) 
One antibody directed to 
the C-terminal and one to 
the N-terminal region 
(amino acids 1-34). 
PTH (1-84) and some circulating 
fragments, especially PTH (7-84), 
but to lesser extent than 1st 
generation methods 
3rd generation From 2000s onwards Immunometric assay 
(frequently referred 
to as “whole” or 
“bioactive” PTH 
assays) 
One antibody directed to 
the C-terminal and one to 
the N-terminal region 
(amino acids 1-4). 
PTH (1-84). Detection of a “big” 
molecular fragment has also been 
reported. 
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Table 2. Evidence-based recommendations for good practice for PTH sample handling and acquisition  
PICO questions Recommendations Strength of 
recommendation 
Comments 
In human blood samples, how 
stable is PTH in EDTA or 
lithium heparin whole blood or 
plasma compared to clotted 
whole blood at 4C, -20C and 
-80C? 
 
If blood samples for PTH measurement are taken into tubes containing 
EDTA, the plasma must be separated from the cells within 24h of 
venepuncture 
 
If blood samples for PTH measurement are taken into “dry” tubes, the serum 
must be separated from the cells as soon as possible, and analyzed within 3-4h 
of venepuncture or stored at -20°C for later analysis. 
 
 
 
EDTA plasma samples for PTH measurement should be stored at 4C and 
analysed within 72h of venepuncture 
 
 
 
 
 
 
 
Strong [24] 
 
 
 
Strong [24] 
 
 
 
 
 
Strong [24] 
Consistent with guidance issued by the Clinical Laboratory Standards 
Institute and the World Health Organisation. 
 
 
The main practical advantage of using serum is that calcium can then be 
measured in the same tube as PTH, since calcium (and bone-alkaline 
phosphatase) cannot be measured in EDTA plasma. If immediate transfer 
of the specimen to the laboratory can be guaranteed, this may be a 
preferred option. 
 
An advantage of EDTA plasma over serum is that PTH in EDTA plasma 
has longer stability at RT than in serum and that delayed centrifugation to 
allow blood to clot is not needed 
 
 
Published evidence is inconsistent regarding the stability of PTH under 
frozen storage conditions. Should laboratories need to freeze plasma prior 
to PTH measurement, they should establish the stability of PTH in frozen 
plasma as measured with their own assay. 
In human blood samples, does 
the sampling site affect PTH 
concentrations? 
Blood samples for PTH measurement should always be collected from the 
same sample site (central or peripheral) for comparison both within and 
between individuals. Clinical guidelines should explicitly state whether 
targets refer to peripheral or central venous concentrations. 
Strong [24] This is particularly relevant in haemodialysis patients, for whom samples 
are often taken through a central line, as PTH concentrations are reported 
to be 30% higher in central blood compared to peripheral blood. 
Similarly, in patients undergoing parathyroidectomy with intra-operative 
PTH monitoring, central venous PTH concentrations were higher 
compared to peripheral venous PTH concentration. Knowledge of local 
practice is highly desirable. 
In human blood samples, does 
the time of sampling affect 
PTH concentrations? 
Season, latitude, renal function and vitamin D status (and perhaps age and 
race) should be considered and/or reported in all studies undertaking reference 
range determinations for PTH and when interpreting PTH results in individual 
patients. Reference intervals must be derived from same sample type (e.g. 
serum, EDTA plasma) than the one that is used routinely in patients samples.  
 
Except for dialysis patients in whom PTH is measured before the dialysis 
session, blood samples for PTH measurement should ideally be collected in 
the early morning in a fasting state and result interpreted against a reference 
interval derived for this sampling time and feeding status. Indeed, serum 
calcium, phosphorus and PTH display significant circadian variations and are 
influenced by food intake (especially calcium-containing foods). 
Assessed as weak [24] 
to strong [28, 31]  
 
 
 
 
Expert opinion 
This is a controversial area. It is difficult to assess whether the observed 
seasonal variation in 25OHD concentration is pathological and not 
normal physiology. The definition of vitamin D sufficiency also varies 
widely (e.g.25OHD concentration from 30 to 110 nmol/L) and the 
relationship between PTH and 25OHD is highly dependent on age. 
There are some concerns about the validity of the data identified and no 
studies addressed the relative diagnostic accuracy of PTH measurement at 
different times of the day.  However, when recruiting a reference 
population to establish PTH reference values, exclusion of any subjects 
who are clinically likely to have either increased or decreased PTH 
concentration would seem appropriate. 
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Figure 1. Schematic diagram showing the changes in calcitriol, FGF23 and PTH with 
increasing stage of CKD. [Figure adapted from Reference [6] and used with 
permission] 
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Figure 2. Between-method differences in the concentration of parathyroid hormone 
(PTH) observed in a typical single patient specimen. Reference intervals for the 
lowest and highest reading immunoassays were similar (1–6.5 and 1.2–7.6 pmol/L) 
respectively) [12]. [Figure from Reference [12] and used with permission.] 
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Figure 3. Relationship between mean method recovery of highly purified synthetic 
PTH(1-84) and cumulative bias from the consensus mean target. [The zero line on the 
y axis represents the consensus mean target.] [UK NEQAS (Edinburgh) data, 2015] 
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Figure 4. Relative recognition of PTH(7-84) in twelve commercially available PTH 
methods. [Highly purified PTH(7-84) was added to a pool of human EDTA plasma 
containing a measurable level of PTH(1-84). [UK NEQAS (Edinburgh) data, 2015] 
[Methods: A, IDS iSYS; B, Siemens Advia Centaur; C, DiaSorin Liaison N-tact II; D, 
Roche Elecsys; E, Tosoh AIA; F, Ortho Vitros; G, Abbott Architect; H, Future 
Diagnostics STAT; I, Beckman Access; J, Siemens Immulite; K, Siemens Immulite 
2000; L, DiaSorin Liaison 1-84 PTH] 
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Figure 5. PTH results obtained by mass spectrometry plotted against the all 
laboratory trimmed consensus mean for 48 UK NEQAS specimens. Results are the 
average of three mass spectrometric analyses for each sample. Circles indicate 
specimens containing plasma from patients with CKD-MBD, squares indicate 
specimens containing PTH IS WHO PTH IS 95/646. [Passing-Bablok slope 0.9926; 
1.0 pmol/L of PTH ~ 9.5 pg/mL] 
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